Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...

Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

For advertisers, it’s an opportunity to get their products in front of millions. Advertisers pull out all the stops for their ...

Plenty of brands are already sharing or teasing their Super Bowl 2025 ads. Here are all the ads we've seen ahead of the big game.

Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.

The healthcare space is a great place to look for these sorts of players because here you'll find all that you need to gain in both growth and security -- from young biotechs developing game ...